The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of recurrence score (RS) performed on pretreatment (Tx) core biopsies (CB) in predicting response to neoadjuvant chemotherapy (NCT) in patients (Pts) with ER+ breast cancer (BC).
Atilla Soran
Research Funding - Genomic Health
Kandace P. McGuire
No relevant relationships to disclose
Gretchen Ahrendt
No relevant relationships to disclose
Marguerite Bonaventura
No relevant relationships to disclose
Priscilla F. McAuliffe
No relevant relationships to disclose
Emilia Diego
No relevant relationships to disclose
Merida Serrano
No relevant relationships to disclose
Ronald Johnson
No relevant relationships to disclose